Background: Vemurafenib, a selective inhibitor of BRAF kinase, is approved for the treatment of adult stage IIIc/IV BRAF V600 mutation-positive melanoma. We conducted a phase I, open-label, dose-escalation study in pediatric patients aged 12-17 years with this tumor type (NCT01519323).
INTRODUCTION
The incidence of melanoma in individuals aged <20 years in the United States is 4.2 cases per 1 million and increasing. 1 Although rare in young children, 73% of melanoma cases before the age of 20 years occur in adolescents aged 15-19 years, with melanoma accounting for 7% of all malignancies in this age group. 2, 3 Approximately 85-90% of pediatric melanoma patients in this age range present with localized disease that is amenable to surgical resection. 4 A further 10% of pediatric patients have resectable disease with regional spread (stage IIIa/IIIb), and there are reports of treatment with high-dose interferon alfa 2b adjuvant therapy. [5] [6] [7] Unresectable (stage IIIc) or metastatic (stage IV) melanoma is exceptionally rare in pediatric patients, and outcome is particularly poor with an estimated 5-year overall survival (OS) of 12-20%. 8, 9 Elucidation of oncogenic mutations in melanoma has led to the development of novel targeted therapies, which have improved survival in adults with advanced melanoma. Approximately 50% of adult melanomas carry a somatic BRAF mutation in codon V600, most commonly V600E, leading to constitutive BRAF activation. [10] [11] [12] [13] BRAF activation results in downstream mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase phosphorylation, and ultimately to the activation of transcription factors responsible for regulating cell cycle and protein synthesis. While not independently sufficient to promote oncogenesis, BRAF V600 mutations are a major regulator of melanoma cell proliferation.
Vemurafenib, a selective inhibitor of BRAF kinase, is indicated for use in adults with BRAF V600 mutation-positive stage IIIc/IV melanoma. 14 The phase III BRAF Inhibitor in Melanoma 3 (BRIM-3) trial compared vemurafenib with dacarbazine in treatment-naïve adult patients with BRAF V600 mutant stage IIIc/IV melanoma. 15 Compared with dacarbazine, vemurafenib significantly improved progressionfree survival (PFS) and OS, and was associated with 63% and 74% relative reductions in the risk of death and in the risk of death or disease progression, respectively (P < 0.001 for both comparisons). 15 Response rates were 48% for vemurafenib and 5% for dacarbazine. 15 The most common adverse events (AEs) associated with vemurafenib during clinical development were arthralgia, rash, fatigue, alopecia, keratoacanthoma, or squamous cell carcinoma (SCC), photosensitivity, nausea, and diarrhea. [15] [16] [17] There is a lack of prospectively evaluated therapies in adolescents with metastatic melanoma. Given the poor outcomes observed in this population 8 and the improved outcomes reported with vemurafenib in adult patients with metastatic melanoma, 15, 17 we conducted a clinical trial of vemurafenib in adolescent patients with BRAF V600 mutationpositive stage IIIc/IV melanoma.
METHODS

Study design
BRAF Inhibitor in Melanoma-Pediatric (BRIM-P; NCT01519323; NO25390) was a phase I, open-label, multicenter, single-arm, doseescalation study of oral vemurafenib in patients aged 12-17 years. The study included a dose-escalation phase, using a 3 + 3 design 18 (see Supplementary Materials), and a planned extension phase where additional patients would be recruited to further evaluate safety and efficacy. The starting dose was 720 mg twice daily (BID) for patients who weighed ≥45 kg; for patients who weighed <45 kg, the starting dose was 480 mg BID regardless of the dose-escalation cohort open at the time of enrollment. All patients were to receive oral vemurafenib at their assigned dose until the maximum tolerated dose (MTD) for the extension phase was determined. 
Study participants
Objectives
The primary objective of the study was to estimate the MTD and identify the recommended dose of oral vemurafenib for pediatric patients aged 12-17 years with unresectable stage IIIc/IV BRAF mutationpositive melanoma. Secondary objectives were evaluations of the safety and tolerability, efficacy, and pharmacokinetic profile of vemurafenib in this population. Exploratory objectives included investigation into potential biomarkers. 
Safety assessments
Efficacy assessments
Pharmacokinetic assessments
Venous blood samples (2 ml) were collected predose (morning), and . Plasma concentrations of vemurafenib were determined using validated liquid chromatography-tandem mass spectrometry. The lower limit of quantitation for vemurafenib in human plasma was 0.025 g/ml, with linearity demonstrable to 50 g/ml (upper limit of quantitation), using a sample volume of 0.05 ml.
Statistical analyses
Target enrollment for the planned extension phase was 20 patients.
The primary analysis variable was the MTD, defined as one dose level below the dose that induced a DLT in at least one of three patients following expansion of that dose level (i.e., two of six patients, or fewer if unacceptable toxicity prohibited further enrollment into a dose level). All safety findings were summarized using descriptive 
Exploratory biomarker assessments
RESULTS
Patients
A total of six patients, all weighing ≥45 kg, were enrolled into two dose cohorts. Three patients received vemurafenib at a dose of 720 mg BID, and three patients subsequently received vemurafenib at a dose of 960 mg BID. Baseline characteristics and prior therapies are presented in 
Safety and tolerability
All six patients received at least one dose of vemurafenib and were included in the safety population. An MTD could not be determined, because no DLTs were observed in the small number of patients enrolled.
All patients experienced at least one AE. The most common AEs (reported in ≥3 patients) were diarrhea and headache (each occurring in four [66.7%] patients), and photosensitivity, rash, nausea, and fatigue (each occurring in three [50%] patients). The majority of AEs were grade 1 or 2 in severity, and four patients experienced grade ≥3 AEs (Table 2 ). There were no AEs leading to discontinuation or dose reduction of vemurafenib. Two patients had an AE (nephrolithiasis, n = 1; skin infection, n = 1) that required vemurafenib to be temporarily withheld.
Serious AEs were reported in three patients during the study (Table 3) . Patient 6, a 16-year-old white male, developed a cutaneous SCC that was considered related to vemurafenib, and the patient concomitantly experienced a cutaneous basal cell carcinoma (BCC; two lesions reported). The patient underwent excision of the SCC and BCC, and no further therapy for these lesions was administered. No patients had a prolongation of QTc > 500 msec.
All six patients discontinued study treatment following disease progression. Five of the six patients died subsequent to disease progression, and four patient deaths were attributed to progressive disease (PD). One death occurred due to an AE of intracranial tumor hemorrhage in a patient with preexisting intracranial disease (Patient 4). The AE occurred 10 days after the patient had discontinued the study drug due to PD (confirmed by brain CT). In the opinion of the investigator, the event of intracranial tumor hemorrhage was not related to the study drug.
Efficacy
All patients were assessed for tumor response during the doseescalation phase and were included in the efficacy population. The Four patients had a BORR status of stable disease for >6 weeks; therefore, the clinical benefit rate was 66.7% (Table 4) . Median PFS was 4.4 months (95% CI = 2.7-5.2), and all six patients subsequently experienced disease progression. Median OS was 8.1 months (95% CI = 5.1-12.0), and one patient was alive at the time of study closure 16.9 months after study drug initiation. No patients were enrolled in the efficacy extension phase.
Pharmacokinetics
All patients had at least one postdose blood sample and were included in the pharmacokinetic population. Individual steady-state plasma concentration-time profiles (day 22) are presented by vemurafenib dose in Figure 1 . Steady-state concentration was relatively constant over the dosing interval in both dose cohorts following oral 
TA B L E 3 Serious AEs
Tumor whole exome sequencing
Whole exome sequencing (WES) was performed in melanoma samples and paired normal blood samples from all six patients. The most prevalent SNVs (Supplementary Figure S2) , and SNVs detected in mitogen-activated protein kinase signaling pathway genes ( Figure 2) and known to be relevant to melanoma, 22-25 are described here.
Eighty-five percent of SNVs was cytidine to thymidine (C > T) or guanine to adenine (G > A) transitions. Supplementary Table S1 shows all coding and noncoding variants (SNVs and indels) as detected by WES in each sample. Figure 2 shows genes affected by copy number gains and losses in each sample. No CNV changes were seen in melanoma-associated genes (Supplementary Table S2 ). In five of six patients, WES confirmed the presence of a BRAF V600E mutation, as originally detected using the Cobas R 4800 BRAF V600 mutation test.
No BRAF V600E mutation could be detected in one patient, likely due
The genomic data for six pediatric melanomas analyzed by Cobas R 4800 BRAF V600 Mutation Test and WES. The mutation load plot displays the number of somatic mutations per Mb. The SNVs shown here are related to the MAPK pathway. The CNV plot lists genes that either have a loss (blue) or a gain (red), or failed samples (gray). CNV, copy number variation; MAPK, mitogen-activated protein kinase; SNV, single nucleotide variation; WES, whole exome sequencing to low quality of formalin-fixed, paraffin-embedded DNA and poor next-generation sequencing coverage (Supplementary Table S3 ). 
DISCUSSION
The tolerability of vemurafenib in the small number of adolescent patients treated during this study was consistent with that observed in adults. The MTD of vemurafenib in pediatric and adolescent patients could not be determined as no DLTs were observed in the six treated patients (720 mg BID, n = 3; 960 mg BID, n = 3). The absence of DLTs should be interpreted cautiously given the small sample size. Secondary cutaneous malignancies (SCC and BCC) were observed in one patient, consistent with previous findings in adults. [15] [16] [17] The pharmacokinetic characteristics of vemurafenib in adolescent patients were generally consistent with those observed in adults. 26 As in adults, substantial accumulation of vemurafenib was observed following multiple BID doses in both dose cohorts. Interindividual variability in vemurafenib exposure was greater following a single dose than at steady state, and steady-state exposure was relatively constant over the dosing interval. Steady-state vemurafenib plasma exposures in adolescent patients were found to be similar or higher than those observed in adults. 26 For example, the mean steady-state C max following vemurafenib 720 mg BID was similar in adolescents (∼50 g/ml) to that observed in adults (∼53 g/ml); in contrast, the mean steady-state plasma concentration following vemurafenib 960 mg BID appeared greater in adolescents (∼93 g/ml) than in adults (∼61 g/ml). 26 Based on the limited data available in this study, a dose recommendation cannot be made for patients with metastatic or unresectable melanoma <18 years of age. Given the established adult MTD of 960 mg BID, and the similar or higher exposure to vemurafenib in adolescents versus adults, further prospective evaluation of vemurafenib doses above 960 mg BID in patients aged <18 years and weighing ≥45 kg is not warranted. This study provides no information about dosing in patients aged <18 years who weigh <45 kg.
Unlike adult patients with BRAF V600-mutated metastatic melanoma, in whom objective responses to vemurafenib have been observed in 48-53% of cases in phase II and III trials, 15, 17 no objective responses were observed in adolescents with this tumor type. This cannot be attributed to drug resistance induced by prior chemotherapeutic intervention, as only two patients received systemic therapy prior to study enrollment. Moreover, the patient with the longest time to disease progression was the only one to receive cytotoxic chemotherapy prior to enrollment. Furthermore, drug exposure was equal to or higher than that observed in adults, and compliance with study drug administration was high. Finally, prolonged periods of study drug withholding due to toxicity or noncompliance did not occur.
Thus, a clinical rationale to explain the apparent inferior outcomes in adolescents relative to adults has not been identified. Given the small sample size, the possibility that the difference may have occurred due to chance cannot be excluded.
Exploratory biomarker analysis detected no previously characterized genetic aberrations associated with resistance to vemurafenib therapy that would explain the lack of drug response (including loss of phosphatase and tensin homolog [PTEN] 27 or neurofibromatosis-1, 28 BRAF copy number amplification, 29 CDK4 mutations and cyclin D1 amplifications, 30 and NRAS or MEK mutations 31 ).
Consistent with previous findings, our results suggest that the pediatric melanoma samples examined in the present study are heterogeneous, with mutations relevant to melanoma oncogenesis occurring in a mutually exclusive manner. 32 The high proportion of C > T and G > A transitions are consistent with damage by ultraviolet radiation. [33] [34] [35] [36] [37] The median mutation load in this pediatric cohort was also consistent with that observed previously in pediatric and adult samples. 32, 38 The primary limitations of this study were its low enrollment and consequent termination, for which there are several potential reasons.
Foremost, metastatic melanoma requiring systemic therapy is exceedingly rare in adolescents. 2 While the annual incidence of melanoma is approximately 4/1,000,000 pediatric patients, 1 metastatic cancer at presentation comprises less than 3% of disease. 8 Additionally, high cure rates of patients with regional disease treated with surgery and high-dose interferon alfa 2b limit the number of patients who recur with metastatic disease later on. [5] [6] [7] Treatment of this adult cancer in adolescents occurs in both pediatric and adult oncology facilities, potentially limiting adequate patient concentration in, and referral to, tertiary study sites. 3, [39] [40] [41] Additionally, the majority of patients with melanoma who were considered for enrollment were BRAF V600 mutation negative, were not within the eligible age range, or had a disease stage that was too low. Finally, the standard-of-care treatment for metastatic melanoma has evolved considerably since the study Our experience highlights the need to identify appropriate solutions for conducting early phase trials in patients <18 years of age with cancers that are more typically seen in adults. Given that similar tolerability, pharmacokinetics, and recommended doses are typically observed in adolescents (relative to adults) in the evaluation of most drugs, 37 the inclusion of adolescents with adult cancers is warranted in early phase trials to facilitate therapeutic development in younger patients. This holds particularly true considering that even a large adolescent multinational study may not recruit sufficient patients and may ultimately provide therapy considered obsolete relative to a rapidly evolving adult therapeutic landscape. Novel collaborative strategies among adult and pediatric centers and study sponsors are needed to facilitate referral of rare adolescent patients to tertiary centers recruiting on such trials. When dedicated phase I pediatric studies are warranted, mechanism-of-action-based enrollment (as opposed to disease-specific enrollment) should be seriously considered so as not to risk successful completion of pharmacokinetic and tolerability objectives or render development of new drugs unfeasible in other potential pediatric indications. The experience of this trial, to which few patients were accrued despite extensive recruitment efforts, highlights the necessity of a multistakeholder approach among academics, regulators, industry sponsors, and advocacy groups to ensure broad pediatric development strategies, proper molecular prioritization, and minimized risk of low-enrolling or nonfeasible trials. 42 In conclusion, a recommended dose of vemurafenib in patients with BRAF V600-mutated metastatic or unresectable melanoma aged <18 years and weighing ≥45 kg was not identified in this study. No new safety signals were observed. No objective tumor responses were observed in this limited pediatric population. Based on limited data from six adolescent patients in two dose groups, the pharmacokinetic characteristics of vemurafenib appeared similar to those in adult patients. Inclusion of adolescents in adult trials and mechanism-ofaction approaches in pediatric trials are critical potential mitigation strategies to ensure the timely evaluation of adolescents with rare diseases and successful completion of pharmacology and tolerability objectives in early phase trials in pediatric-aged patients.
